Disc Medicine, Inc. (IRON) 10-Year Financial Performance & Capital Metrics

IRON • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutDisc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.Show more

Revenue $0
EBITDA -$130M -42.3%
Net Income -$109M -43.1%
EPS (Diluted) -3.96 -15.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -27.73% +5.4%
ROIC -72.61%
Debt/Equity 0.07 +1010.9%
Interest Coverage -226.78

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 80 (top 20%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 23.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-75.02%

EPS CAGR

10Y-

5Y-

3Y-

TTM-33.42%

ROCE

10Y Avg-50.63%

5Y Avg-50.63%

3Y Avg-34.47%

Latest-31.64%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	322K	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	-322K	0	0	0	0
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	1%	-	-	-
Operating Expenses+	33.72M	30.93M	47.48M	91.13M	129.72M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	5.87M	5.76M	14.04M	21.86M	33.05M
SG&A % of Revenue	-	-	-	-	-
Research & Development	28.17M	25.17M	33.44M	69.26M	96.67M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	-322K	0	0	0	0
Operating Income+	-34.04M	-30.93M	-47.48M	-91.13M	-129.72M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	0.09%	-0.53%	-0.92%	-0.42%
EBITDA+	-33.72M	-30.9M	-47.39M	-91.03M	-129.56M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	0.08%	-0.53%	-0.92%	-0.42%
D&A (Non-Cash Add-back)	322K	32K	89K	100K	156K
EBIT	-34.01M	-30.93M	-47.48M	-76.33M	-108.43M
Net Interest Income+	-6.79M	-2.14M	709K	14.8M	20.72M
Interest Income	37K	14K	709K	14.8M	21.29M
Interest Expense	6.83M	2.16M	0	0	572K
Other Income/Expense	-6.8M	-5.04M	648K	14.79M	20.72M
Pretax Income+	-40.84M	-35.97M	-46.83M	-76.33M	-109M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	99K	355K
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-40.84M	-35.97M	-46.83M	-76.43M	-109.36M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	0.12%	-0.3%	-0.63%	-0.43%
Net Income (Continuing)	-40.84M	-35.97M	-46.83M	-76.43M	-109.36M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-27.02	-44.88	-45.05	-3.42	-3.96
EPS Growth %	-	-0.66%	-0%	0.92%	-0.16%
EPS (Basic)	-27.02	-44.88	-45.05	-3.42	-3.96
Diluted Shares Outstanding	1.51M	801.47K	1.04M	22.32M	27.61M
Basic Shares Outstanding	1.51M	801.47K	1.04M	22.32M	27.61M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.07M	90.48M	198.49M	365.66M	493.62M
Cash & Short-Term Investments	4.5M	88.04M	194.61M	360.38M	489.88M
Cash Only	4.5M	88.04M	194.61M	360.38M	192.43M
Short-Term Investments	0	0	0	0	297.45M
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	-802K	0	0	3.73M
Total Non-Current Assets+	3.25M	1.93M	1.71M	2.33M	3.16M
Property, Plant & Equipment	294K	1.75M	1.6M	2.1M	2.32M
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	2.96M	180K	116K	234K	838K
Total Assets+	8.32M	92.41M	200.21M	368M	496.77M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	10.11%	1.17%	0.84%	0.35%
Total Current Liabilities+	24.88M	13.42M	22.58M	21.44M	23.32M
Accounts Payable	2.38M	2.56M	16.16M	12.63M	7.95M
Days Payables Outstanding	2.69K	-	-	-	-
Short-Term Debt	16.69M	5M	0	0	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	0	1.45M	3.62M	5.79M	7.21M
Current Ratio	0.20x	6.74x	8.79x	17.06x	21.17x
Quick Ratio	0.20x	6.74x	8.79x	17.06x	21.17x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	5.3M	143.19M	1.03M	1.44M	29.87M
Long-Term Debt	4.95M	404K	0	0	28.32M
Capital Lease Obligations	0	1.33M	1.03M	1.44M	1.55M
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	353K	141.45M	0	0	0
Total Liabilities	30.18M	156.61M	23.61M	22.88M	53.19M
Total Debt+	21.64M	7.06M	1.33M	2.1M	30M
Net Debt	17.14M	-80.98M	-193.28M	-358.28M	-162.43M
Debt / Equity	-	-	0.01x	0.01x	0.07x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-4.99x	-14.33x	-	-	-226.78x
Total Equity+	-21.86M	-64.2M	176.6M	345.12M	443.59M
Equity Growth %	-	-1.94%	3.75%	0.95%	0.29%
Book Value per Share	-14.46	-80.11	169.89	15.47	16.07
Total Shareholders' Equity	-21.86M	-64.2M	176.6M	345.12M	443.59M
Common Stock	2K	0	2K	2K	3K
Retained Earnings	-112.82M	-65.39M	-112.22M	-188.65M	-298M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	0	289K
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-32.71M	-27.53M	-42.25M	-73.46M	-93.93M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	0.16%	-0.53%	-0.74%	-0.28%
Net Income	-40.84M	-35.97M	-46.83M	-76.43M	-109.36M
Depreciation & Amortization	322K	32K	89K	100K	156K
Stock-Based Compensation	983K	507K	2.09M	5.53M	16.82M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	6.49M	6.61M	272K	290K	-4.77M
Working Capital Changes	337K	1.29M	2.13M	-2.95M	3.23M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	-2.41M	1.31M	526K	-3.74M	-4.68M
Cash from Investing+	-22K	-68K	-151K	-89K	-292.33M
Capital Expenditures	-22K	-68K	-151K	-89K	-505K
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	34.25M	89.93M	148.98M	239.38M	218.31M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	163K	4.65M	95.48M	40.3M	2.02M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-32.73M	-27.6M	-42.4M	-73.55M	-94.43M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	0.16%	-0.54%	-0.73%	-0.28%
FCF per Share	-21.65	-34.44	-40.79	-3.30	-3.42
FCF Conversion (FCF/Net Income)	0.80x	0.77x	0.90x	0.96x	0.86x
Interest Paid	345K	307K	0	0	198K
Taxes Paid	0	0	0	112K	299K

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-83.32%	-29.3%	-27.73%
Return on Invested Capital (ROIC)	-	-	-	-	-72.61%
Debt / Equity	-	-	0.01x	0.01x	0.07x
Interest Coverage	-4.99x	-14.33x	-	-	-226.78x
FCF Conversion	0.80x	0.77x	0.90x	0.96x	0.86x

Frequently Asked Questions

Growth & Financials

Disc Medicine, Inc. (IRON) grew revenue by 0.0% over the past year. Growth has been modest.

Disc Medicine, Inc. (IRON) reported a net loss of $181.1M for fiscal year 2024.

Dividend & Returns

Disc Medicine, Inc. (IRON) has a return on equity (ROE) of -27.7%. Negative ROE indicates the company is unprofitable.

Disc Medicine, Inc. (IRON) had negative free cash flow of $166.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener